The U.S. Supreme Court is set to decide whether fishing companies must pay for third-party observers to monitor compliance with regulations, which could impact how the FDA interacts with regulated industries. This decision may overturn the Chevron deference doctrine, which supports regulatory agency interpretations of laws when ambiguous. A separate case involving mifepristone could also shake up the regulatory framework for medicines and affect FDA approvals. Changes to Chevron deference could lead to challenges in Medicare and Medicaid matters, with implications for drug approvals and definitions. Ultimately, overturning Chevron deference could have a significant impact on how cases are decided in the future.
Source link
Why a SCOTUS Ruling on Fishing Rules Could Change How FDA Regulates Drugs
